Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EXP012
- Development stage
- Preclinical
- Lead developer
- Excalipoint Therapeutics
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
EXP012 is a trispecific antibody T cell engager being developed by Excalipoint Therapeutics for the treatment of gastrointestinal cancers, including colorectal, gastric, and pancreatic cancers. The molecule is designed to simultaneously bind to Cadherin-17 (CDH17), which is overexpressed in gastrointestinal tumors, and the immune cell targets CD3 (on T cells) and 4-1BB (a co-stimulatory receptor). By engaging these three targets, EXP012 aims to recruit and activate T cells specifically within the tumor microenvironment to enhance anti-tumor immunity. The drug was licensed from Lepu Biopharma and is currently in preclinical development, with clinical trials anticipated to begin in 2026.
- Other names
- CDH17-CD3-4-1BB tri-specific T cell engagerCDH-17-CD3-4-1BB tri-specific T cell engagerCDH 17-CD3-4-1BB tri-specific T cell engagerCDH17-CD3-4-1BB TriAbCDH-17-CD3-4-1BB TriAbCDH 17-CD3-4-1BB TriAb
02
Targets
TNFRSF9 (CD137 extracellular domain)CDH17 (Cadherin-17)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on EXP012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EXP012.